Key facts
- The UK is exploring the use of libido-suppressing drugs for sex offenders.
- The treatment pathway, called MMPSA, will expand to 20 prisons in November.
- A potential national rollout of voluntary drug treatment for sex offenders is targeted for December 2028.
- Drugs include SSRIs to limit invasive sexual thoughts and anti-androgens to reduce testosterone.
- Ministers are reconsidering a pledge to explore mandatory chemical castration for serious sex offenders.
The UK is considering expanding the voluntary use of libido-suppressing drugs for thousands of male prisoners convicted of sexual offenses, with a potential national rollout by December 2028. The treatment pathway, known as MMPSA, aims to manage problematic sexual arousal by using medications like SSRIs to limit intrusive thoughts and anti-androgens to reduce testosterone production. This initiative is part of a broader effort to address prison overcrowding.
Professor Belinda Winder, who has evaluated these medications, stated that approximately one in four sex offenders, or 3,750 current prisoners, would be considered for the treatment. The pilot program is set to expand from 10 to 20 prisons in November, extending into new NHS regions. Winder expressed optimism for a properly resourced, voluntary national pathway, emphasizing the need for clinical support alongside medication.
However, ministers are re-evaluating a previous pledge to explore mandatory chemical castration for serious sex offenders. Experts like Winder have raised concerns about the feasibility and ethical implications of a mandatory approach, citing potential breakdowns in trust and significant resource demands. They also noted that these drugs are not permanent and require consistent adherence to be effective, distinguishing them from actual castration.
Prison campaigners and union representatives have urged caution. Critics point to the potential for severe side effects from long-term testosterone suppression, such as osteoporosis and cardiovascular disease, and the limited data from randomized controlled trials. They stress that participation must remain voluntary and that the history of prison-based treatment programs has been troubled.